Use of allopurinol to manage skewed 6-mercaptopurine metabolism in pediatric maintenance acute lymphoblastic leukemia treatment.
Mandee LinesRyan M KemperJordan WallaceThomas B AlexanderCarmen D EcholsLauren M GarnerJenna Bognaski KaplanPatrick ThompsonDaniel J CronaKynlon PhillipsPublished in: European journal of haematology (2024)
Allopurinol significantly increased the percent time in therapeutic ANC range and can be safely utilized to significantly lower the ratio of 6MMP:6TGN metabolites, alleviating the undesirable side effects of 6MMP, and optimizing the anti-leukemic effects associated with 6TGN.